Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

NeuroRx announced yesterday preliminary findings from the phase 2b/3 trial of the intravenous delivery form of RLF-100™. According to NeuroRx, the preliminary data suggest that the administration of intravenous RLF-100™ could reduce the length of hospital stay among patients with respiratory failure due to critical COVID-19 compared to placebo plus maximal standard of care. No unexpected side effects were identified. The most common side effects of RLF-100™ in the clinical trial were mild to moderate diarrhea and systemic hypotension (low blood pressure). All potentially serious adverse effects were investigated by a board-certified critical care physician together with site investigators; none were deemed drug related.

https://relieftherapeutics.com/newsblog/relief-confirms-release-of-preliminary-findings-from-phase-2b-3-trial-of-intravenous-rlf-100-aviptadil